{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:52:53Z","timestamp":1787241173235,"version":"build-2736575974"},"reference-count":35,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2025,4,17]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This cost-effectiveness analysis compares vonoprazan against lansoprazole, a gold-standard proton pump inhibitor, in managing erosive oesophagitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The economic evaluation was carried out using data from a double-blind, randomised control trial. Costs were measured in pounds sterling. Effectiveness was assessed on a binary scale, resolution versus non-resolution of disease, after 32 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The primary analysis produced an incremental cost-effectiveness ratio (ICER) of \u00a33421.27 per resolution. After applying quality-adjusted life year (QALY) data from the REFLUX trial (2008), we derived an ICER\/QALY of \u00a334 747.32, marginally exceeding the \u00a330\u2009000 threshold set by the National Institute for Health and Care Excellence. However, further subgroup analysis showed cost-effectiveness when healing severe grades of oesophagitis (ICER\/QALY of \u00a322 165.56). The first sensitivity analysis considers the typically non-invasive determination of disease resolution; the ICER\/QALY of \u00a315\u2009826.98 supports vonoprazan\u2019s use in treating severe oesophagitis. The second considers a longer healing phase alongside a stronger 30\u2009mg maintenance dose of lansoprazole, concordant with current guidelines; the ICER\/QALY of \u00a343\u2009998.39 suggests the guidelines (regarding dosage, frequency and duration) must be optimised for vonoprazan. The final sensitivity analysis accounts for variations in quality-of-life measures, which grossly inflate the ICER\/QALY (\u00a3118 216.32); this emphasises that vonoprazan should mainly be considered for patients with persistent symptoms and high severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Vonoprazan is potentially cost-effective for the initial healing of severe oesophagitis, after endoscopic diagnosis. Further trials and economic evaluations are necessary for the symptom-based prescription of vonoprazan and to determine the optimal dosage, frequency and duration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2024-001709","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T15:55:12Z","timestamp":1747065312000},"page":"e001709","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating the cost-effectiveness of replacing lansoprazole with vonoprazan for treating erosive oesophagitis"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4149-5620","authenticated-orcid":false,"given":"Saeash","family":"Jeyarajan","sequence":"first","affiliation":[{"name":"Business School, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6648-0375","authenticated-orcid":false,"given":"Thejasvin","family":"K","sequence":"additional","affiliation":[{"name":"Whittington Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5002-4409","authenticated-orcid":false,"given":"Sneha","family":"Pimpalnerkar","sequence":"additional","affiliation":[{"name":"Business School, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9107-3586","authenticated-orcid":false,"given":"Emily Zichu","family":"Deng","sequence":"additional","affiliation":[{"name":"Business School, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8814-5869","authenticated-orcid":false,"given":"Zain","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Business School, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5753-380X","authenticated-orcid":false,"given":"Diya","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Business School, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1684-9397","authenticated-orcid":false,"given":"Laure","family":"de Preux","sequence":"additional","affiliation":[{"name":"Imperial College Business School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"2026010701052225000_12.1.e001709.1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2982.2005.00661.x","article-title":"The lower oesophageal sphincter","volume":"17","author":"Boeckxstaens","year":"2005","journal-title":"Neurogastroenterology Motil"},{"key":"2026010701052225000_12.1.e001709.2","unstructured":"BMJ Best Practice . Homepage. 2023. Available: https:\/\/bestpractice.bmj.com\/info\/ [Accessed 10 Mar 2025]."},{"key":"2026010701052225000_12.1.e001709.3","unstructured":"NICE . Recommendations | Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management | Guidance. 2014. Available: https:\/\/www.nice.org.uk\/guidance\/cg184\/chapter\/Recommendations [Accessed 10 Mar 2025]."},{"key":"2026010701052225000_12.1.e001709.4","unstructured":"Endoscopy Campus . Reflux esophagitis: Los Angeles classification. 2025. Available: https:\/\/www.endoscopy-campus.com\/en\/classifications\/reflux-esophagitis-los-angeles-classification\/ [Accessed 10 Mar 2025]."},{"key":"2026010701052225000_12.1.e001709.5","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-008-0098-4"},{"key":"2026010701052225000_12.1.e001709.6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.36469\/jheor.2024.90924","article-title":"Budget Impact of RefluxStopTM as a Treatment for Patients with Refractory Gastro-oesophageal Reflux Disease in the United Kingdom","volume":"11","author":"Harper","year":"2024","journal-title":"J Health Econ Outcomes Res"},{"key":"2026010701052225000_12.1.e001709.7","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1080\/07853890.2022.2074535","article-title":"Global, regional and national burden of gastroesophageal reflux disease, 1990-2019: update from the GBD 2019 study","volume":"54","author":"Zhang","year":"2022","journal-title":"Ann Med"},{"key":"2026010701052225000_12.1.e001709.8","unstructured":"NHSBSA . Prescription cost analysis \u2013 England 2023\/24. 2023. Available: https:\/\/www.nhsbsa.nhs.uk\/statistical-collections\/prescription-cost-analysis-england\/prescription-cost-analysis-england-202324 [Accessed 10 Mar 2025]."},{"key":"2026010701052225000_12.1.e001709.9","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221122623","article-title":"The role of vonoprazan in patients with erosive esophagitis","volume":"15","author":"Zhang","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"2026010701052225000_12.1.e001709.10","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.2169\/internalmedicine.2535-18","article-title":"Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan","volume":"58","author":"Habu","year":"2019","journal-title":"Intern Med"},{"key":"2026010701052225000_12.1.e001709.11","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00535-019-01609-2","article-title":"Cost-utility analysis of a \u201cvonoprazan-first\u201d strategy versus \u201cesomeprazole- or rabeprazole-first\u201d strategy in GERD","volume":"54","author":"Yokoya","year":"2019","journal-title":"J Gastroenterol"},{"key":"2026010701052225000_12.1.e001709.12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jgf2.429","article-title":"Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: A cost-effectiveness analysis in Japan","volume":"22","author":"Habu","year":"2021","journal-title":"J Gen Fam Med"},{"key":"2026010701052225000_12.1.e001709.13","doi-asserted-by":"crossref","DOI":"10.21037\/atm-22-1722","article-title":"Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China","volume":"10","author":"Wang","year":"2022","journal-title":"Ann Transl Med"},{"key":"2026010701052225000_12.1.e001709.14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.gastro.2022.09.041","article-title":"Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial","volume":"164","author":"Laine","year":"2023","journal-title":"Gastroenterology"},{"key":"2026010701052225000_12.1.e001709.15","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/jgh.14664","article-title":"Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review","volume":"34","author":"Miyazaki","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"2026010701052225000_12.1.e001709.16","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318365"},{"key":"2026010701052225000_12.1.e001709.17","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13461"},{"key":"2026010701052225000_12.1.e001709.18","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-311304"},{"key":"2026010701052225000_12.1.e001709.19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2021.04.491","article-title":"PGI1 Vonoprazan Versus Proton-Pump Inhibitors for the Management of Severe Reflux Esophagitis: A Systematic Review and Network Meta-Analysis","volume":"24","author":"Zhang","year":"2021","journal-title":"Value Health"},{"key":"2026010701052225000_12.1.e001709.20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000497775","article-title":"Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux","volume":"101","author":"Akiyama","year":"2020","journal-title":"Digestion"},{"key":"2026010701052225000_12.1.e001709.21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/apt.15062","article-title":"Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis","volume":"49","author":"Oshima","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026010701052225000_12.1.e001709.22","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031807","article-title":"Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis","volume":"101","author":"Yang","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"2026010701052225000_12.1.e001709.23","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3748\/wjg.v24.i14.1550","article-title":"Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole","volume":"24","author":"Ashida","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2026010701052225000_12.1.e001709.24","first-page":"183","article-title":"Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review","volume":"17","author":"Chinzon","year":"2022","journal-title":"Prz Gastroenterol"},{"key":"2026010701052225000_12.1.e001709.25","unstructured":"Medicinal forms | Lansoprazole | Drugs | BNF content published by NICE. 2025. Available: https:\/\/bnf.nice.org.uk\/drugs\/lansoprazole\/medicinal-forms\/ [Accessed 10 Mar 2025]."},{"key":"2026010701052225000_12.1.e001709.26","unstructured":"Vonoprazan. Cambridge Bioscience Limited; 2025. Available: https:\/\/www.bioscience.co.uk\/product~1034516 [Accessed 10 Mar 2025]."},{"key":"2026010701052225000_12.1.e001709.27","unstructured":"NHS England . 2023-25 NHS payment scheme (amended). 2023. Available: https:\/\/www.england.nhs.uk\/publication\/2023-25-nhs-payment-scheme\/ [Accessed 10 Mar 2025]."},{"key":"2026010701052225000_12.1.e001709.28","unstructured":"Speer R . Erosive esophagitis: what is it? - Preferred research partners. Preferred Research Partners; 2020. Available: https:\/\/preferredresearchpartners.com\/erosive-esophagitis-what-is-it\/#:~:text=Erosive%20esophagitis%20is%20a%20severe,of%20reflux%2C%20or%20stomach%20acid [Accessed 10 Mar 2025]."},{"key":"2026010701052225000_12.1.e001709.29","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826090-00004"},{"key":"2026010701052225000_12.1.e001709.30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta12310","article-title":"The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease - a UK collaborative study. The REFLUX trial","volume":"12","author":"Grant","year":"2008","journal-title":"Health Technol Assess"},{"key":"2026010701052225000_12.1.e001709.31","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.4.502"},{"key":"2026010701052225000_12.1.e001709.32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jpge.2015.07.004","article-title":"Biopsies in Gastrointestinal Endoscopy: When and How","volume":"23","author":"Peixoto","year":"2016","journal-title":"GE Port J Gastroenterol"},{"key":"2026010701052225000_12.1.e001709.33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1572-0241.2000.01759.x","article-title":"A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease","volume":"95","author":"Gerson","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"2026010701052225000_12.1.e001709.34","unstructured":"NICE . Guide to the methods of technology appraisal 2013. 2013. Available: https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781"},{"key":"2026010701052225000_12.1.e001709.35","unstructured":"Garlick S . Ethnic group, England and Wales [Office for National Statistics]. 2022. Available: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/culturalidentity\/ethnicity\/bulletins\/ethnicgroupenglandandwales\/census2021 [Accessed 10 Mar 2025]."}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2024-001709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:05:44Z","timestamp":1767776744000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2024-001709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,12]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bmjgast-2024-001709"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2024-001709","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}